PIM1 and neoplasm: Because AZD1208 is no longer a clinical candidate due to toxicity in clinical trials, we also verified these results in PC3 xenograft tumor sections previously isolated from mice treated with PIM447 [35], a PIM inhibitor that has an improved safety profile and is currently being tested in Phase II/III clinical trials.